MedTrace Logo

Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia

NCT00276601 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2014-04-17

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.

PURPOSE: This phase II trial is studying how well giving combination chemotherapy works in treating patients with acute promyelocytic leukemia.

Conditions

Interventions

DRUG

arsenic trioxide

DRUG

cytarabine

DRUG

daunorubicin hydrochloride

DRUG

mercaptopurine

DRUG

methotrexate

DRUG

tretinoin

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    lead OTHER

Principal Investigators

  • Steven D. Gore, MD · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Study Design

Purpose
TREATMENT

Eligibility

Min Age
5 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-10-31
Primary Completion
2007-12-31
Completion
2013-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00276601 on ClinicalTrials.gov